protein degradation

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

News

Seagen partners Nurix on 'degrader-antibody conjugates'

Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu

News

Astellas builds in protein degraders with PeptiDream deal

Astellas has made another move into the area of protein degrader drugs, announcing its second partnership in the category in the space of two months.

News

Astellas extends protein degrader drive with Cullgen deal

Astellas has become the latest big pharma to pledge big bucks to a smaller company working on protein degraders, paying $35 million upfront to partner with US start-up Cul

News

Merck gets stuck on Proxygen’s molecular glue degraders

Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology.

News